Engineering Non-Human Proteins with Machine Learning to Reduce Immunogenicity
Time: 3:00 pm
day: Conference Day Two
Details:
- Demonstrate how AI-driven platforms can redesign bacterial-derived proteins to reduce immunogenicity and enhance therapeutic potential
- Validating assays and strategies to reliably evaluate immunogenicity risks during drug development
- Removing T-cell and B-cell epitopes to tackle stability and manufacturability
